Pharsight

Drug Patents Expiring in 2027

1. Abilify patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-633) Feb 16, 2014
Pediatric Exclusivity(PED) Aug 27, 2011
Orphan Drug Exclusivity(ODE) Dec 12, 2021
M(M-137) Jun 09, 2017
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL; TABLET;ORAL; SOLUTION;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(2 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patien...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

3. Abraxane patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034375

(Pediatric)

BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-658) Oct 11, 2015
Pediatric Exclusivity(PED) Jun 06, 2023
M(M-14) Dec 06, 2022
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

4. Actoplus Met patents expiration

ACTOPLUS MET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-116) May 17, 2015

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ACTOPLUS MET family patents

Family Patents

5. Acular Ls patents expiration

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8008338 ABBVIE Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008338

(Pediatric)

ABBVIE Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(3 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage

ACULAR LS family patents

Family Patents

6. Admelog Solostar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7918833 SANOFI-AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 11, 2020

Drugs and Companies using INSULIN LISPRO ingredient

Market Authorisation Date: 11 December, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage

ADMELOG SOLOSTAR family patents

Family Patents

7. Adrenaclick patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352 IMPAX Kits containing medicine injection devices and containers
Apr, 2027

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ADRENACLICK family patents

Family Patents

8. Advil Allergy Sinus patents expiration

ADVIL ALLERGY SINUS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(2 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ADVIL ALLERGY SINUS family patents

Family Patents

9. Akeega patents expiration

AKEEGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 JANSSEN BIOTECH DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8143241 JANSSEN BIOTECH DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient

Market Authorisation Date: 11 August, 2023

Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation

Dosage: TABLET;ORAL

More Information on Dosage

AKEEGA family patents

Family Patents

10. Alsuma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter
Aug, 2027

(3 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 29 June, 2010

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

ALSUMA family patents

Family Patents

11. Altabax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 12, 2012

Drugs and Companies using RETAPAMULIN ingredient

NCE-1 date: 13 April, 2011

Market Authorisation Date: 12 April, 2007

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

Family Patents

12. Amitiza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(2 years from now)

US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(2 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-670) Apr 19, 2016
M(M-225) Apr 26, 2021

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

13. Ampyra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007826 ACORDA Sustained release aminopyridine composition
May, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2015
Orphan Drug Exclusivity(ODE) Jan 22, 2017

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage

AMPYRA family patents

Family Patents

14. Amyvid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(3 years from now)

US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 06, 2017

Drugs and Companies using FLORBETAPIR F-18 ingredient

NCE-1 date: 06 April, 2016

Market Authorisation Date: 06 April, 2012

Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMYVID family patents

Family Patents

15. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8511304

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

16. Antizol patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7553863 PAR PHARM INC Ultrapure 4-methylpyrazole
Jun, 2027

(3 years from now)

Drugs and Companies using FOMEPIZOLE ingredient

Market Authorisation Date: 04 December, 1997

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of ANTIZOL before it's drug patent expiration?
More Information on Dosage

ANTIZOL family patents

Family Patents

17. Apidra Solostar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7918833 SANOFI AVENTIS US Pen-type injector
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 24, 2011

Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient

Market Authorisation Date: 24 February, 2009

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

APIDRA SOLOSTAR family patents

Family Patents

18. Argatroban In Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7589106 CIPLA Alcohol free formulation of argatroban
Sep, 2027

(3 years from now)

US7687516 CIPLA Alcohol free formulation of argatroban
Sep, 2027

(3 years from now)

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 29 June, 2011

Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ARGATROBAN IN SODIUM CHLORIDE before it's drug patent expiration?
More Information on Dosage

ARGATROBAN IN SODIUM CHLORIDE family patents

Family Patents

19. Arnuity Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 17, 2021
New Patient Population(NPP) May 17, 2021
New Product(NP) Aug 20, 2017
M(M-290) Mar 01, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

20. Aubagio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Apr 30, 2024
New Chemical Entity Exclusivity(NCE) Sep 12, 2017
Pediatric Exclusivity(PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

21. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(2 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(2 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(3 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

22. Aveed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(2 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 05, 2017

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage

AVEED family patents

Family Patents

23. Axiron patents expiration

AXIRON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2013

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.; A method of increasing the test...

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's drug patent expiration?
More Information on Dosage

AXIRON family patents

Family Patents

24. Azilect patents expiration

AZILECT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-685) May 29, 2017

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

More Information on Dosage

AZILECT family patents

Family Patents

25. Balcoltra patents expiration

BALCOLTRA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7838042 AVION PHARMS Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
Jun, 2027

(3 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2018

Treatment: Administration of ferrous bisglycinate tablets

Dosage: TABLET;ORAL

How can I launch a generic of BALCOLTRA before it's drug patent expiration?
More Information on Dosage

BALCOLTRA family patents

Family Patents

26. Belbuca patents expiration

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(3 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 23, 2018

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Treatment of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's drug patent expiration?
More Information on Dosage

BELBUCA family patents

Family Patents

27. Beleodaq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH BIOPHARMA Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 03, 2021
New Chemical Entity Exclusivity(NCE) Jul 03, 2019
Orphan Drug Exclusivity(ODE-68) Jul 03, 2021

Drugs and Companies using BELINOSTAT ingredient

NCE-1 date: 03 July, 2018

Market Authorisation Date: 03 July, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage

BELEODAQ family patents

Family Patents

28. Bosulif patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767678

(Pediatric)

PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
May, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2017
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030
New Indication(I-923) Sep 26, 2026
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
Pediatric Exclusivity(PED) Mar 26, 2027

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 27 October, 2017

Treatment: NA

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

29. Breo Ellipta patents expiration

BREO ELLIPTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(3 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(3 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(3 years from now)

US8511304

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-202) May 15, 2020
New Product(NP) May 10, 2016
New Chemical Entity Exclusivity(NCE) May 10, 2018
New Indication(I-708) Apr 30, 2018
Pediatric Exclusivity(PED) Nov 13, 2026
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 10 May, 2013

Treatment: Maintenance treatment of asthma in patients aged 5 years and older. recommended dosages: breo 100/25 or 200/25 ages 18 years and older; Breo 100/25 ages 12-17 years, and breo 50/25, ages 5-11 years

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

30. Brixadi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236292 BRAEBURN Liquid depot formulations
Jan, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BRIXADI family patents

Family Patents

31. Bunavail patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(3 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 06, 2017

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's drug patent expiration?
More Information on Dosage

BUNAVAIL family patents

Family Patents

32. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-240) Feb 15, 2022
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
New Patient Population(NPP) Jul 22, 2024
M(M-224) Apr 02, 2021
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 28 February, 2014

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

33. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
New Product(NP) Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

34. Bydureon Pen patents expiration

BYDUREON PEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element
Nov, 2027

(3 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-240) Feb 15, 2022
New Product(NP) Jan 27, 2015
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
New Patient Population(NPP) Jul 22, 2024
M(M-224) Apr 02, 2021
Pediatric Exclusivity(PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 28 February, 2014

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

35. Byfavo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 06, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 06 October, 2024

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

Family Patents

36. Byvalson patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838552 ABBVIE Compositions comprising nebivolol
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jun 03, 2019

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's drug patent expiration?
More Information on Dosage

BYVALSON family patents

Family Patents

37. Cabenuva Kit patents expiration

CABENUVA KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

38. Camcevi Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646572 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(2 years from now)

US9744207 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(2 years from now)

US9572857 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage

CAMCEVI KIT family patents

Family Patents

39. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2008

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents

Family Patents

40. Cardene In 0.86% Sodium Chloride In Plastic Container patents expiration

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2008

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents

Family Patents

41. Cardene In 4.8% Dextrose In Plastic Container patents expiration

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2008

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER family patents

Family Patents

42. Cardene In 5.0% Dextrose In Plastic Container patents expiration

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(3 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2008

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER before it's drug patent expiration?
More Information on Dosage

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER family patents

Family Patents

43. Chloraprep With Tint patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7422388 BECTON DICKINSON CO Applicator for coloring antiseptic
Apr, 2027

(3 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 14 July, 2000

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SPONGE;TOPICAL

More Information on Dosage

CHLORAPREP WITH TINT family patents

Family Patents

44. Chlorhexidine Gluconate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7935093 SAGE PRODS Disinfectant delivery system and method of providing alcohol-free disinfection
Oct, 2027

(3 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

Family Patents

45. Colazal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)

US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Dec 20, 2013
Pediatric Exclusivity(PED) Jun 20, 2014

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 18 July, 2000

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage

COLAZAL family patents

Family Patents

46. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

47. Contrave patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107837 NALPROPION Sustained release formulation of naltrexone
Jun, 2027

(3 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations
Nov, 2027

(3 years from now)

US10307376 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

US9125868 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

US8722085 NALPROPION Methods for administering weight loss medications
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Sep 10, 2017

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion in a layered formulation for chronic weight m...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage

CONTRAVE family patents

Family Patents

48. Corlanor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Jun, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
Pediatric Exclusivity(PED) Oct 15, 2020

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

NCE-1 date: 16 October, 2019

Market Authorisation Date: 15 April, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage

CORLANOR family patents

Family Patents

49. Cotellic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
Pediatric Exclusivity(PED) Jan 28, 2026
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

50. Cresemba patents expiration

CRESEMBA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(3 years from now)

US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE-458) Dec 08, 2030
New Patient Population(NPP) Dec 08, 2026
Orphan Drug Exclusivity(ODE) Mar 06, 2022
Pediatric Exclusivity(PED) Jun 08, 2031
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
ODE*(ODE*) Mar 06, 2022
Orphan Drug Exclusivity(ODE-454) Dec 08, 2030

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

51. Daklinza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(3 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-727) Feb 05, 2019
New Indication(I-726) Feb 05, 2019
New Chemical Entity Exclusivity(NCE) Jul 24, 2020
New Dosing Schedule(D-161) Feb 05, 2019
New Dosing Schedule(D-162) Feb 05, 2019

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

NCE-1 date: 25 July, 2019

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus; Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity

Dosage: TABLET;ORAL

More Information on Dosage

DAKLINZA family patents

Family Patents

52. Dexilant patents expiration

Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Feb, 2027

(2 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
Pediatric Exclusivity(PED) Jul 30, 2012
New Patient Population(NPP) Jul 08, 2019

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

53. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Mar, 2027

(2 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(3 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-367) Jan 24, 2027
Pediatric Exclusivity(PED) Jul 24, 2023
New Product(NP) Jan 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

54. Dovato patents expiration

DOVATO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

55. Dsuvia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252328 VERTICAL PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(2 years from now)

US10342762 VERTICAL PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(2 years from now)

US8231900 VERTICAL PHARMS Small-volume oral transmucosal dosage
Jan, 2027

(2 years from now)

US10245228 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US10507180 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US8778393 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US8865211 VERTICAL PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(2 years from now)

US8778394 VERTICAL PHARMS Small-volume oral transmucosal dosage forms
Jan, 2027

(2 years from now)

US8535714 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US9320710 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US8252329 VERTICAL PHARMS Bioadhesive drug formulations for oral transmucosal delivery
Jan, 2027

(2 years from now)

US8226978 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

US9744129 VERTICAL PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Jan, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 02, 2021

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

DSUVIA family patents

Family Patents

56. Duaklir Pressair patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8051851 COVIS Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
Apr, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Mar 29, 2022

Drugs and Companies using ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

DUAKLIR PRESSAIR family patents

Family Patents

57. Duavee patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7683051 WYETH PHARMS Crystalline polymorph of bazedoxifene acetate
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 13, 2018
New Product(NP) Oct 03, 2016

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

NCE-1 date: 13 October, 2017

Market Authorisation Date: 03 October, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage

DUAVEE family patents

Family Patents

58. Duetact patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
Jan, 2027

(2 years from now)

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage

DUETACT family patents

Family Patents

59. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206737 ABBVIE Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

60. Dyanavel Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675703 TRIS PHARMA INC Modified release formulations containing drug - ion exchange resin complexes
Mar, 2027

(2 years from now)

US8597684 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8883217 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US10086087 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 19, 2018

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 19 October, 2015

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR family patents

Family Patents

61. Dyanavel Xr 10 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR 10 family patents

Family Patents

62. Dyanavel Xr 15 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR 15 family patents

Family Patents

63. Dyanavel Xr 20 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR 20 family patents

Family Patents

64. Dyanavel Xr 5 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes
Mar, 2027

(2 years from now)

Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient

Market Authorisation Date: 04 November, 2021

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

DYANAVEL XR 5 family patents

Family Patents

65. Dyloject patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292 JAVELIN PHARMS INC Formulations of low dose diclofenac and beta-cyclodextrin
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 23, 2017

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 23 December, 2014

Treatment: Management of pain

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of DYLOJECT before it's drug patent expiration?
More Information on Dosage

DYLOJECT family patents

Family Patents

66. Edluar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(2 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

67. Elepsia Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163306 TRIPOINT Oral drug delivery system
Sep, 2027

(3 years from now)

US8431156 TRIPOINT Pharmaceutical composition
Oct, 2027

(3 years from now)

US8470367 TRIPOINT Oral drug delivery system
Oct, 2027

(3 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

ELEPSIA XR family patents

Family Patents

68. Embeda patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682634 ALPHARMA PHARMS Pharmaceutical compositions
Jun, 2027

(3 years from now)

US8877247 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Jun, 2027

(3 years from now)

US8158156 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
Jun, 2027

(3 years from now)

US7682633 ALPHARMA PHARMS Pharmaceutical composition
Jun, 2027

(3 years from now)

US8846104 ALPHARMA PHARMS Pharmaceutical compositions for the deterrence and/or prevention of abuse
Jun, 2027

(3 years from now)

US7815934 ALPHARMA PHARMS Sequestering subunit and related compositions and methods
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 13, 2012

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering an intact composition as claimed.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EMBEDA before it's drug patent expiration?
More Information on Dosage

EMBEDA family patents

Family Patents

69. Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Mar 19, 2013
New Patient Population(NPP) Aug 28, 2018

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 30 June, 2006

Treatment: Prevention of postoperative nausea and vomiting

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

70. Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents

71. Empaveli patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(3 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(3 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-288) Feb 08, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026
Orphan Drug Exclusivity(ODE-351) May 14, 2028

Drugs and Companies using PEGCETACOPLAN ingredient

NCE-1 date: 14 May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

EMPAVELI family patents

Family Patents

72. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(3 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Apr 01, 2023
M(M-82) Feb 16, 2024
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

73. Epiduo patents expiration

EPIDUO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 08, 2011
New Patient Population(NPP) Feb 01, 2016

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

74. Erleada patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(2 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-808) Sep 17, 2022
New Chemical Entity Exclusivity(NCE) Feb 14, 2023

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: 14 February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc)

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage

ERLEADA family patents

Family Patents

75. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient
Dec, 2027

(3 years from now)

US7696326 GENENTECH INC Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfen...

Dosage: CAPSULE;ORAL; TABLET;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

76. Eucrisa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(2 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-191) Apr 03, 2026
New Chemical Entity Exclusivity(NCE) Dec 14, 2021
Pediatric Exclusivity(PED) Sep 23, 2023
New Patient Population(NPP) Mar 23, 2023

Drugs and Companies using CRISABOROLE ingredient

NCE-1 date: 23 September, 2022

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's drug patent expiration?
More Information on Dosage

EUCRISA family patents

Family Patents

77. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(2 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(2 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(3 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

78. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(2 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(2 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(3 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

79. Fanapt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586610 VANDA PHARMS INC Methods for the administration of iloperidone
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 06, 2014
M(M-180) May 26, 2019

Drugs and Companies using ILOPERIDONE ingredient

NCE-1 date: 06 May, 2013

Market Authorisation Date: 06 May, 2009

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage

FANAPT family patents

Family Patents

80. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-238) Feb 22, 2022
M(M-298) May 08, 2026
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

81. Fiasp Flextouch patents expiration

FIASP FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 24 September, 2018

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

82. Fibricor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569612 ATHENA Methods of use of fenofibric acid
Aug, 2027

(3 years from now)

US7741374 ATHENA Methods of use of fenofibric acid
Aug, 2027

(3 years from now)

US7741373 ATHENA Methods of use of fenofibric acid
Aug, 2027

(3 years from now)

US7915247 ATHENA Methods of use of fenofibric acid
Aug, 2027

(3 years from now)

Drugs and Companies using FENOFIBRIC ACID ingredient

Market Authorisation Date: 14 August, 2009

Treatment: Adjunctive therapy to diet in patients with hyperlipidemias; Adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels; Adjunctive therapy to diet to patients with hypertrig...

Dosage: TABLET;ORAL

More Information on Dosage

FIBRICOR family patents

Family Patents

83. Finacea patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700076 LEO PHARMA AS Penetrating pharmaceutical foam
Sep, 2027

(3 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier
Oct, 2027

(3 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 29, 2018

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage

FINACEA family patents

Family Patents

84. Flolipid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300041 TCG FLUENT PHARMA Liquid oral simvastatin compositions
Apr, 2027

(3 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Market Authorisation Date: 21 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage